TD Cowen downgraded Inozyme (INZY) to Hold from Buy with a $4 price target after BioMarin Pharmaceutical (BMRN) agreed to acquire the company for $4.00 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INZY:
- Inozyme Pharma’s Strategic Acquisition by Biomarin: Analyst Holds Rating Amid Favorable Shareholder Outcome and Strategic Alignment
- Inozyme downgraded to Neutral from Overweight at Piper Sandler
- Inozyme downgraded to Hold from Buy at Jefferies
- Leerink bullish on BioMarin following Inozyme deal, expects additional BD
- Inozyme downgraded to Market Perform from Outperform at Raymond James